Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $1.00 price target on the stock.

Separately, Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock opened at $1.10 on Tuesday. Lyell Immunopharma has a 1-year low of $0.85 and a 1-year high of $3.26. The company has a fifty day simple moving average of $1.21 and a 200 day simple moving average of $1.68. The company has a market cap of $307.14 million, a P/E ratio of -1.39 and a beta of -0.47.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.03 million for the quarter. On average, equities research analysts forecast that Lyell Immunopharma will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in Lyell Immunopharma by 1.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock valued at $15,013,000 after buying an additional 92,594 shares in the last quarter. State Street Corp grew its holdings in shares of Lyell Immunopharma by 1.9% during the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Lyell Immunopharma in the first quarter valued at approximately $7,482,000. TD Asset Management Inc raised its holdings in Lyell Immunopharma by 4.2% in the 2nd quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after buying an additional 40,800 shares during the last quarter. Finally, Invenomic Capital Management LP boosted its position in Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock worth $1,944,000 after buying an additional 125,110 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.